Chicharros USA - bolsa internacional

Cytr

Menudo ojo tienes!!! Buenísima compra!!!🇪🇸🇪🇸

Gracias tio, gracias.

IDXG

Las compre por esto:

BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced the formal launch of the TERT marker of aggressiveness in indeterminate thyroid nodules at the Third World Congress on Thyroid Cancer being held in Boston, MA through Saturday, July 29^th.   Over 1200 domestic and international delegates gathered during the meeting.  Along with launching TERT, the Company served as a major sponsor of the event in support of the meeting’s objective to educate physicians and others about diagnosing and treating thyroid cancer.   

The TERT marker is a strong molecular predictor of the aggressiveness of thyroid cancer and adds additional insights into a patient’s molecular profile.  Currently, the ThyGenX™ mutation panel includes the following markers that are predictive of thyroid cancer from cytologically indeterminate thyroid nodules: BRAF, HRAS, KRAS, NRAS, RET/PTC, PAX8/PPARy, and PIK3CA.  By adding TERT, the panel will not only continue to be a strong positive predictor of thyroid cancer, but will also provide evidence that a positive result indicates the cancer is likely to be more aggressive in nature. 

Published data indicates that TERT mutations can extend the life span of tumor cells and allow time for other mutations to develop. Mutations in the TERT promoter region are found in thyroid cancers and seem to act synergistically when they occur with the BRAF V600 mutation.  The coexistence of mutations in TERT and BRAF genes has been shown to dramatically increase the risk of thyroid cancer aggressiveness, tumor recurrence and thyroid cancer-specific deaths. 

Physicians are now able to order TERT as part of the ThyGenX mutation panel or on an individual basis. 

The ThyGenX /ThyraMIR® test is the only test in the market that combines the rule-in properties of Next Generation Sequencing of a patient's DNA and RNA, and the rule-out capabilities of a micro-RNA classifier.  Based on current performance, over 80% of the Company’s total cases are reflexed to ThyraMIR for additional assessment.  The Company first launched ThyGenX in October 2014 and ThyraMIR on April 15^th, 2015, making both tests available to Endocrinologists and Pathologists throughout the country.  Since then, the Company has conducted over 15,000 ThyGenX/ThyraMIR tests for nearly 400 physicians and hospitals nationwide. 

According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the US, tripling in the past three decades. Most physicians have traditionally recommended thyroid surgery where thyroid nodule biopsy results are indeterminate, not clearly benign or malignant following traditional cytopathology review, however 70-80% of these surgical outcomes are ultimately benign.  Molecular testing using ThyGenX /ThyraMIR has been shown to reduce the rate of unnecessary surgeries in indeterminate cases.

Jack E. Stover, President and CEO of Interpace, stated, “We are pleased to officially launch the TERT product extension at the World Congress on Thyroid Cancer. This is the appropriate setting and audience for bringing this important service to the market.

Desde luego.. Eleu y "sus sustos"...

DARE

Se supone que con la de hoy, ya son 8 jornadas en rojo. ¿Qué dicen los expertos en estudiar las jornadas?

DARE

Sí, es tremendo... ayer lo comentaba aquí.. todas las sesiones en rojo desde el reverse... Ya está más del 50% abajo desde el precio por el que salió.. Y hoy está bajando, y sigue casi en los mínimos del día... Yo, de momento, sólo miro...

DARE

Yo, en como sigan bajando, en 2.70 las ensillo seguro, aunque sigan bajando luego, que por estadística le tiene que tocar gato por esos precios, no tiene que tardar mucho en metérselo.

CYTR

Me pareció ver un lindo gatito.....